However, the human sample data on DAPK1 and tau SUMOylation is correlative, and a definitive validation of the DAPK1/SENP1/tau-SUMOylation axis in the development of tauopathy and other AD pathologies would require the use of human AD patient-derived induced pluripotent stem cells for disease modeling. This evidence concerns the gene MAPT and Alzheimer disease.